Noerr advises DUBAG Group on the acquisition of JPT Peptide Technologies GmbH from BioNTech

A Noerr team led by Markus A. Braun and Georg Schneider has advised the LEO III Fund managed by the DUBAG Group on its acquisition of JPT Peptide Technologies GmbH from BioNTech Diagnostics GmbH.

Founded in 2004 as a spin-off from Jerini AG, JPT is one of the leading international providers of peptide-based research and development solutions. Operating from Berlin, the company serves more than 20,000 customers in over 100 countries across biopharma, cell and gene therapy, vaccine development, immunology, proteomics and academic research. As a stand-alone company under the LEO III Fund, JPT will continue to invest in its technology platform, aims to accelerate its international development across Europe and North America, and plans to further diversify its portfolio of peptide solutions.

The DUBAG Group is a specialised Munich-based investment advisory team with a proven track record. DUBAG manages Private Equity Funds, which aim at the acquisition and active development of companies in special situations. 

Advisors to DUBAG Group: Noerr

PE/Corporate: Markus A. Braun (Associated Partner), Georg Schneider (Partner, joint lead), John Jun (Senior Associate), Teresa Seibold (Senior Associate), Amélie Louisa Bitzer (Associate)

Real Estate: Manuel Lomb (Associated Partner), Luca Lowsky (Associate)

Employment: Boris Blunck (Partner)

Finance: Pinar Turkac-Christmann (Associated Partner)

Public Law: Hendrik Schlutt (Counsel)

Regulatory: Fabian Hübener (Partner), Sven Betzendörfer (Senior Associate)

Tax: Elmar Bindl (Partner), Nico Rosenfelder (Senior Associate), Maximilian Schischke (Senior Associate), Nicole Wistop (Counsel)